Gastric Motility Disorder Drug Market is Primed for Growth Due to Rising Geriatric Population

Global Gastric Motility Disorder Drug Market
Global Gastric Motility Disorder Drug Market



Market Overview
Gastric motility disorder drugs are indicated for the treatment of gastrointestinal motility disorders such as gastroparesis, a condition characterized by delayed gastric emptying. The key marketed drugs include metoclopramide, domperidone, erythromycin, and botulinum toxin. Orally administered drugs like metoclopramide and domperidone help improve gastric emptying and relieve nausea and vomiting. Botox injections aid in relieving gastric dysrhythmias by paralyzing part of the pylorus muscle. The rising prevalence of disorders like gastroparesis due to diabetes and other neurological conditions has fueled the demand for gastric motility disorder drugs.

The Global Gastric Motility Disorder Drug Market is estimated to be valued at US$ 83.15 Bn in 2024 and is expected to exhibit a CAGR of 5.4% over the forecast period from 2024 to 2031.


Key Takeaways
Key players operating in the gastric motility disorder drug market are Pfizer Inc., Takeda Pharmaceutical Company Limited, Janssen Pharmaceuticals, Sun Pharmaceutical Industries Ltd., AbbVie Inc., Boehringer Ingelheim, Eli Lilly and Company, Bristol Myers Squibb, Daiichi Sankyo Company, Limited, Bausch Health Companies, Mallinckrodt Pharmaceuticals, Endo Pharmaceuticals, Eisai Co., Ltd., Ferring Pharmaceuticals, UCB, Evoke Pharma, and Cadila Pharmaceuticals. These players are engaged in developing advanced drug formulations and pipeline drugs to expand their product portfolios.

The growing prevalence of diabetes worldwide presents significant opportunities for drug manufacturers in the gastric motility disorder market. Diabetic gastroparesis accounts for over 80% of all gastroparesis cases. Rising awareness about gastroparesis as a complication of diabetes is driving more patients to seek medical treatment.

Key players are focusing on expanding their geographic presence and stepping up initiatives in high growth emerging markets such as Asia Pacific, Middle East, and Latin America. Strategic acquisitions and partnerships are enabling companies to strengthen distribution networks and market position globally.

Market Drivers
Rising Geriatric Population: The risk of developing gastric motility disorders increases with age. According to the United Nations, over 16% of the global population will be aged 65 years and above by 2050. This vast geriatric demographic presents a solid patient base for gastric motility drugs.

High Disease Burden of Diabetes: Diabetes is a leading cause of gastroparesis. As per IDF estimates, over 537 million adults globally had diabetes in 2021. Effective treatment of gastroparesis in diabetic patients helps control blood sugar levels and prevent complications. This fuels demand for gastric motility enhancing drugs.

Market Restraints
Stringent Regulatory Approvals: New drug formulations and pipeline drugs require extensive clinical testing and regulatory clearances like FDA approval before commercial launch. This significantly increases costs and delays market entry.

Side Effects of Drugs: Drugs used to treat gastric disorders can cause adverse effects like acute dystonic reactions, fatigue, headaches, and extrapyramidal symptoms in some patients. This hampers medication adherence and overall treatment effectiveness.


Segment Analysis

The gastric motility disorder drug market is dominated by the prokinetic agents sub segment, which holds around 50% market share. Prokinetic agents directly target the gastrointestinal tract and stimulates gastric emptying by increasing gastrointestinal motility or the movement of digesting food through the GI tract. They are preferred for the treatment of gastric motility disorders due to their direct mechanism of action in enhancing gastric emptying and promoting digestive motility.

The antiemetic sub segment is the second largest segment in the gastric motility drug market. Antiemetics are used to prevent and treat nausea and vomiting associated with gastric motility disorders. Drugs belonging to 5-HT3 receptor antagonists and dopamine antagonists are majorly prescribed antiemetic drugs for conditions like gastroparesis.

Global Analysis

Regionally, North America dominates the global gastric motility disorder drug market and holds over 40% market share. Higher illness awareness, well-established healthcare infrastructure and availability of advanced treatment options drive the North American market. Asia Pacific is the fastest growing region due to rising geriatric population, improving healthcare spending and increasing investments by key players in developing countries. However, limited diagnostic facilities and low treatment seeking rates in developing Asia Pacific countries are major challenges. Europe is the second largest market globally, with Germany, UK and France being the major country markets due to supportive government initiatives and funding for gastrointestinal disorder treatment.

Post a Comment

Previous Post Next Post